Researchers at the Institute of Pediatrics, Catholic University Medical School, Rome, Italy reported their observation of side effects of a new form of the drug DDAVP in the Turkish Journal of Urology.
DDAVP (Desmopressin) is sometimes used as a treatment for bedwetting. However, many pediatricians don’t rely on it as a first line therapy because of its potentially severe side effects. Most parents also don’t want their child to take the drug because it works by preventing the formation of urine, which is one of the ways the body eliminates toxins. In addition, many children resume wetting the bed when DDAVP therapy is discontinued.
This studied observed the rate of severe side effects (adverse reactions) in 237 children using a new form of DDAVP that melts under the tongue. The researchers state that the new form makes the drug more available to the body and thus can be prescribed in lower doses.
They found that there were fewer severe side effects overall with the most common being psycho-behavioral and the second most common being neurological. Examples of these adverse reactions were irritability, aggression, poor attention and headache. Lesser seen were abdominal pain, nausea, vomiting, difficulty falling asleep, and fatigue.
For parents who prefer a natural non-drug approach to ending bedwetting instead of waiting to outgrow it, an educational nonprofit such as Dry Kid Academy may be the right path. Using educational principles and motivational methods, parents and children work together as a family to help their child wake up Dry every morning.
For more information about the new form of medication ask your chikd’s pediatrician. To find out if your child is eligible for Dry Kid Academy answer a few questions in the brief survey at drykid.com